Novocure (NSDQ:NVCR) today touted the results of a Phase II pilot trial designed to test the feasibility, safety and efficacy of its Tumor Treating Fields therapy in patients with unresectable, advanced pancreatic cancer.
The St. Helier, N.J.-based company’s Optune device uses electric fields, called Tumor Treating Fields, to disrupt cell division, inhibit tumor growth and trigger cell death in tumors.
Get the full story at our sister site, Drug Delivery Business News.
The post Novocure touts Phase II pancreatic cancer pilot study appeared first on MassDevice.